ClinicalTrials.gg
CompletedNCT07217041Updated Oct 15, 2025

Fluid Status of Dialysis Subjects

An observational study in ESRD (End Stage Renal Disease), sponsored by HemoCept Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-10-15.

Sponsored by HemoCept Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 988 studies in Renal Insufficiency, Chronic with a site in United States — 168 open to participants now, 215 under way, 25 of them phase 3. Renal Insufficiency, Chronic · United States.

Enrollment
146th of 165
12 · median 125
Started
2025
with 56 others
Observational
167 of 988
44 open now
Registered
928th of 988
by date

Among the 988 studies in Renal Insufficiency, Chronic with a site in United States, this one is the 146th largest by enrollment of the 165 observational ones that give a count, is one of 57 that started in 2025, is one of 167 observational ones, and was the 928th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

168 of the 988 studies in Renal Insufficiency, Chronic with a site in United States are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 988 studies in Renal Insufficiency, Chronic with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical pilot study is to evaluate the ability of the device to properly detect the hydration status of the subject through the study of fluid removal data during dialysis and HemoCept device data.

03

Conditions studied

  • ESRD (End Stage Renal Disease)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects between (and including) the ages of 18 and 75 and who meet all the Inclusion/Exclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study or representatives must have voluntarily signed the form before any study related procedures
  • Subjects can be any gender, but must be between (and including) 18 and 75 years of age
  • Subject has been on dialysis for more than 90 days and has been diagnosed with end stage kidney disease
  • Subject is willing and able to provide informed consent and HIPAA authorization • Subject is able and willing to meet all study requirements
  • Subject is able to place electrodes on bilateral deltoids and above the pant line on the waist

Exclusion criteria

Exclusion Criteria:

  • Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
  • Subject has a personal medical history that includes:

    • Long Q-T syndrome
    • Cardiac channelopathies, genetic heart defects
    • Seizures
    • Acute untreated blood clotting disorders or acute untreated bleeding disorders
  • Subject has had a heart transplant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Correlation between HemoCept device and changes in dry weight.

    The primary end point will be to determine if there is a correlation between HemoCept device data and dry weight changes during dialysis. The primary analysis will be conducted at specific points during dialysis treatment: prior to dialysis, in the middle of the dialysis session, and immediately following the completion of dialysis treatment.

    Time frame: At specified points during dialysis treatment for 9 dialysis sessions, over the course of 3 weeks.

Secondary outcomes

  1. Device-related adverse events: device-related adverse events included all adverse events classified as definitely, probably, possibly, or undetermined relation to the device or procedure

    All secondary endpoints will be summarized descriptively, and no hypothesis tests are planned.

    Time frame: From enrollment until the completion of 9 dialysis sessions, over a period of 3 weeks.

07

Study locations

1 site
  • Sierra Nevad Specialty Care
    Reno, Nevada 89511, United States
08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make IPD available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in May 2025, 1 month.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's 1 month is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 15, 2025
StartActual
Mar 19, 2025
Primary completionActual
May 12, 2025
CompletionActual
Jun 9, 2025
Last update
Oct 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07217041
Lead sponsor
HemoCept Inc.
Responsible party
Sponsor
First posted
Oct 15, 2025
Start date
Mar 19, 2025
Primary completion
May 12, 2025
Completion
Jun 9, 2025
Last update
Oct 15, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion